Lovenox injection solution 6000 Anti-IU/0.6 ml of prophylactic treatment of venous thrombosis (2 tubes)

Dosage form 2 -tube box
Specifications Enoxaparin sodium

Ingredient

Thành phần cho 0.6ml

Composition information	Content
Enoxaparin sodium	60mg

Uses

Indications

Lovenox 6000 drug is indicated in the following cases:

Treatment of deep vein thrombosis has been formed, with or without pulmonary embolism, no serious clinical signs, except for pulmonary embolism, which is likely to need to be treated with thrombolytic drugs or by surgery. The level of ST segment has a difference, used in combination with a sufficient or unable to regenerate the coronary regeneration.

The drug has higher resistance to IIA resistance or thrombin resistance.

The drug does not affect much for APTT.

In the treatment dose

With the maximum active peak, APTT can last from 1.5 to 2.2 times the control time. This extension of APTT reflects the residual thrombin activity.

pharmacokinetic pharmacokinetics

Enoxaparin pharmacokinetics parameters are evaluated based on changes in anti -resistance and IIA resistance in plasma at recommended doses (verified amidson resolution methods) after subcutaneous injections and repeated doses and after intravenous injection.

Biological comfort

Enoxaparin subcutaneously absorbed and completely absorbed (nearly 100 %). The active peak in plasma is noticed for 3 to 4 hours after the injection. This active peak (represented by an international unit (IU) Anti - Xa) is 0.18 ± 0.04 anti - Xa IU (after the dose of 2,000 IU), 0.43 ± 0.11 anti - Xa IU (after the dose of 4,000 IU) in preventive treatment, and 1.01 ± 0.14 anti - far (after the dose of 10,000 IU) while used as a treatment method. Skin 100 IU anti - far/kg every 12 hours leads to the first peak of the resistance concentration - the distance is 1.16 IU/ml (n = 16) and the average exposure level corresponds to 88% of the concentration in a stable state. The stable state of concentration is achieved on the second day of treatment. The variation in each patient and between patients is low. After subcutaneous injection, repeat 4,000 anti - far from IU once a day for healthy volunteers, the stable state of concentration is achieved on the 2nd day with the average Enoxaparin activity higher than the value achieved after a single dose of about 15%. Enoxaparin activity level is in a stable state that can be predicted from pharmacokinetics after the single dose injection. 0.52 anti - far from IU/ml. Based on the pharmacokinetics Enoxaparin sodium, the difference in stable state of this concentration has been expected and is within the therapy limit. After subcutaneous injection. Anti -IIA activity in plasma is about 10 times lower than the anti -anti -anti -active activity. Anti -IIA activity on average is noticed about 3 to 4 hours after subcutaneous injection and reaches 0.13 IU anti -IIA/mL after repeating 100 anti - far IU/kg twice a day.

The voltage of anti -anti -active distribution of Enoxaparin is about 5 liters and is nearly equal to the blood volume.

Metabolism

Enoxaparin is metabolized mainly in the liver (reducing sulfate, stool disinfection).

Elimination

After subcutaneous injection, low molecular weight heparin has the apparent half-life of anti-xa activity than heparin without segmentation. disappears from plasma faster than anti-xa activity.

High -risk populations

Elderly patients:

Because the reduced renal function has a physiological properties on this population, the elimination will be slower. This change does not require adjusting the dose or number of injections in the prophylactic treatment as long as the kidney function of these patients is still in an acceptable limit, which is only slightly reduced. discharging creatinine> 30 ml/minute): In some cases, it is recommended to monitor the activity of resistance - the distant factor in the blood to prevent overdose when taking Enoxaparin with thorough dose.

Before taking Lovenox injection solution 6000 Anti-IU/0.6 ml of prophylactic treatment of venous thrombosis (2 tubes)

How to use

subcutaneous injection (except for patients with myocardial infarction, which should be used in the original vein doses). Do not intramuscularly.

Dosage

Dosage depends on indications and patients.

Treatment of deep vein thrombosis, with or without pulmonary embolism, no serious clinical signs.

All cases of deep vein thrombosis should be quickly confirmed by appropriate examination.

Injection and dose schedule

Enoxaparin can be injected under the skin once a day at a dose of 150 anti - far IU/kg or injected twice a day with a dose of 100 anti - far from IU/kg. On patients there are disorders of complications of thrombosis, the recommended dose is 100 anti - far away IU/kg twice a day. Enoxaparin dose is not evaluated in terms of weight in patients with weight greater than 100 kg or less than 40 kg. The effectiveness of Enoxaparin treatment in patients weighing over 100 kg may be slightly lower, and the risk of bleeding in patients weighing less than 40 kg may be higher. These patients need separate clinical monitoring.

Deep venous thrombotic treatment time

Low molecular weight heparin treatment should be quickly replaced with oral anticoagulant resistance, unless contraindicated. Treatment time with heparin weight from low is no more than 10 days, including the time needed to achieve the desired anticoagulant effect when taking oral medication, unless it is difficult to achieve this effect. Therefore, it is advisable to start treating anticoagulants as soon as possible.

Treatment of unstable angina/myocardial infarction without q

Enoxaparin injected subcutaneously with a dose of 100 anti - Xa IU/kg twice a day, 12 hours apart, the lungs are suitable for aspirin (recommended dose: Take 75 to 325 mg, after a minimum loading dose is 160 mg). Coordinate with thrombolytic drugs in patients with sufficient or not eligible for coronary regeneration then

Intravenous intestine initially 3,000 anti - Xa IU, followed by subcutaneous injection with 100 anti - Xa IU/kg within 15 minutes, and then every 12 hours (maximum of 10,000 anti - Xa IU for the first 2 subcutaneous doses). The first Enoxaparin dose must be injected from 15 minutes before 30 minutes after the beginning of the therapy (whether specific with fibrin or not). The recommended treatment time is 8 days, or until the patient is discharged from the hospital if the hospital stay is less than 8 days.

If Enoxaparin is last subcutaneously within 8 hours before pumping the ball, no additional dose injected.

If Enoxaparin is injected subcutaneously for the last time for more than 8 hours before pumping the ball, an additional dose of 30 anti-lu/kg veins must be injected. To ensure the right volume, it is advisable to dilute the drug into a concentration of 300 lu/ml (see the technical section of intravenous injection (loaded dose) is only used to treat acute myocardial infarction with the difference of ST segment).

For patients aged 75 and over

Treatment of acute myocardial infarction has a difference of ST, not injected with the original vein. Should be injected under the skin with a dose of 75 anti - far IU/kg every 12 hours (maximum 7,500 anti - far away IU for the first two injections).

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?
What to do when forgetting a dose?

Side Effects

When using Lovenox 6000 , you may experience unwanted effects (ADR).

Bleeding inside or outside at different levels of severity, must immediately notify the doctor or nurse. Hemorrhage may start due to bleeding lesions, kidney failure or by simultaneously used with some other drugs. Therefore, regular monitoring of the number of bridges. These signs will disappear naturally and do not need to stop treatment.

In some very rare cases, nerve damage has been reported after injecting this drug in some anesthetic procedures.

Please inform the doctor or pharmacist to know all unwanted or uncomfortable effects that have not been stated in this guide.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Lovenox 6000 drugs in the following cases:

If patients are allergic to preparations, heparin, or heparin derivatives, including other low molecular weight heparin.

If the patient previously had severe thrombocytopenia caused by heparin (platelets play an important role in blood clotting).

If patients have coagulation disorders.

If the patient is bleeding or there is a risk of uncontrolled bleeding.

Brain hemorrhage.

If the patient has severe renal failure (unless the fertilizer).

Contraindications for spinal anesthesia/external anesthesia during thorough treatment.

If the patient has acute endocarditis.

The drug is not recommended in the following cases:

in combination with aspirin (at an analgesic and antipyretic dose), nonsteroidal anti -inflammatory drugs, or dextran (drugs used in emergency resuscitation).

In the first days after the stroke does not hemorrhage.

Mild to medium renal failure.

Precautions when using

to avoid bleeding, it is necessary not to overdose the dosage and treatment time that the doctor has prescribed.

Treatment requires repeated blood tests to regularly check the number of platelets (usually twice a week).

During heparin treatment, the number of platelets in a significant way may occur in some rare cases. This requires stop treatment of heparin and strengthen monitoring because there may be serious complications, especially in play with normal thrombosis. This drug is usually not recommended for children.

Like all other anticoagulants, hemorrhage may occur. If bleeding occurs, you must find the cause and initiate treatment.

In some cases, especially in thorough treatment, there may be hemorrhage:

Older patients.

Weight under 40 kg.

kidney failure.

If the treatment continues to exceed the common treatment time of 10 days.

Used in combination with some drugs (see interactions with other drugs and other interactions).

Used in combination with some drugs that increase the risk of bleeding (see interaction with other drugs and other interactions).

These situations need special monitoring: general examination and may have to take blood tests.

If you are or have liver or kidney disease, ulcers or another lesions can burn blood, let your doctor know.

Need to adjust the dose for patients with liver failure, kidney failure (non -dialysis).

Lovenox cannot be used swap (from unit to unit) with conventional heparin (not segmented) or heparin with other low molecular weight.

The ability to drive and operate machinery

No report.

Pregnancy

This drug is not recommended during pregnancy. If you find yourself pregnant during treatment, consult your doctor because only a doctor can assess whether or not to continue treatment.

Breastfeeding period

This drug is not contraindicated in women who are breastfeeding.

Normally, when pregnant or breastfeeding, you should consult your doctor or pharmacist before taking any medicine.

Medicine interaction

because of the possibility of bleeding, always have to tell the doctor if you are taking one of the following drugs:

aspirin.

Non -steroid anti -inflammatory drugs (NSAIDs).

Platelet inhibitors ( abciximab , eftifibatid, iloprost , ticlopidin, tiroflban).

Dextran (drug used in emergency resuscitation).

Oral anticoagulant (inhibitors of vitamin K).

To avoid possible interactions between drugs, always inform the doctor or pharmacist about what you are taking.

The doctor will adjust the appropriate treatment.

Storage

Store at a temperature not exceeding 30 ° C.

The drug must be kept in the packaging before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.